US 2024/0342255 A1Published application

Targeting 3-ketodihydrosphingosine reductase (kdsr) in cancer

AssigneeUniversity of Massachusetts

InventorsDohoon KIM, Meghan SPEARS, Namgyu LEE

Life of this patent

Estimating the term…

Abstract

Provided herein are methods for treating cancer using an inhibitor of KDSR, a precursor of 3KDS (e.g., palmitate), 3KDS itself, or a combination thereof.

Claims17

Dependent claims

A method for treating a cancer, the method comprising administering to a subject in need thereof an effective amount of an inhibitor of 3-ketodihydrosphingosine reductase (KDSR), a precursor of 3-ketodihydrosphingosine (3KDS), 3KDS, or a combination thereof.

Dependencies are inferred from the claim text.

Facts

Application: 18/682,548Filed 11 Aug 2022
Priority: 12 Aug 2021
Published: 17 Oct 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification21 codes

A61K 38/465
Hydrolases: acting on ester bonds , e.g. lipases, ribonucleases
A61K 31/20
Carboxylic acids, e.g. valproic acid: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
A61K 31/7105
Compounds having three or more nucleosides or nucleotides: natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine,…
A61K 31/713
Compounds having three or more nucleosides or nucleotides: double-stranded nucleic acids or oligonucleotides

Family

Application63/232,413Us provisional application · filed 12 Aug 2021
US 2024/0342255 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results